Stock Analysis on Net
Stock Analysis on Net

Edwards Lifesciences Corp. (NYSE:EW)

This company has been moved to the archive! The financial data has not been updated since February 14, 2022.

Balance Sheet: Liabilities and Stockholders’ Equity 
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Edwards Lifesciences Corp., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in thousands

Microsoft Excel
Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017
Accounts payable 204,500 139,500 — — — — — — — — — — — — — — — — — —
Accrued and other liabilities 802,300 802,800 — — — — — — — — — — — — — — — — — —
Accounts payable and accrued liabilities (legacy) — — 861,100 772,500 866,700 822,100 849,400 722,000 876,900 751,700 673,200 623,900 876,600 661,200 584,000 674,100 753,200 693,700 562,500 584,800
Operating lease liabilities, current portion 25,500 24,200 25,100 26,500 27,200 24,200 23,800 24,900 25,500 24,100 23,800 22,600 — — — — — — — —
Short-term debt — — — — — — — — — — — — — 599,900 599,200 598,600 598,000 — — —
Contingent consideration liabilities — — — — — — — — — — — — — — — 41,800 51,700 41,500 — —
Current liabilities 1,032,300 966,500 886,200 799,000 893,900 846,300 873,200 746,900 902,400 775,800 697,000 646,500 876,600 1,261,100 1,183,200 1,314,500 1,402,900 735,200 562,500 584,800
Long-term debt 595,700 595,500 595,400 595,200 595,000 594,900 594,700 594,600 594,400 594,200 594,100 593,900 593,800 593,600 593,900 456,000 438,400 1,034,000 1,016,800 847,900
Contingent consideration liabilities 62,000 80,100 79,000 181,600 186,100 180,900 189,900 170,300 172,500 191,000 193,300 185,300 178,600 192,600 199,000 196,300 192,600 140,500 198,700 195,600
Taxes payable 190,000 190,200 190,200 215,300 215,300 214,200 214,200 239,300 236,600 236,500 236,700 259,400 259,400 264,500 263,300 290,800 394,000 — — —
Operating lease liabilities, long-term portion 69,100 64,400 63,700 67,100 72,700 71,000 66,000 55,700 58,900 52,400 50,400 49,700 — — — — — — — —
Uncertain tax positions 259,000 245,400 234,200 224,200 214,400 199,200 181,300 175,900 171,700 141,700 139,500 130,300 124,900 — — — — — — —
Litigation settlement accrual 191,300 201,400 211,700 222,100 233,000 — — — — — — — — — — — — — — —
Other liabilities 267,300 275,500 268,400 250,800 252,400 484,000 465,700 192,300 203,300 159,900 162,200 156,700 150,000 285,100 282,500 321,800 311,700 416,200 420,900 409,400
Long-term liabilities 1,634,400 1,652,500 1,642,600 1,756,300 1,768,900 1,744,200 1,711,800 1,428,100 1,437,400 1,375,700 1,376,200 1,375,300 1,306,700 1,335,800 1,338,700 1,264,900 1,336,700 1,590,700 1,636,400 1,452,900
Total liabilities 2,666,700 2,619,000 2,528,800 2,555,300 2,662,800 2,590,500 2,585,000 2,175,000 2,339,800 2,151,500 2,073,200 2,021,800 2,183,300 2,596,900 2,521,900 2,579,400 2,739,600 2,325,900 2,198,900 2,037,700
Preferred stock, $.01 par value, no shares outstanding — — — — — — — — — — — — — — — — — — — —
Common stock, $1.00 par value 642,000 641,200 640,100 637,500 636,400 635,000 633,500 218,500 218,100 217,500 216,900 216,000 215,200 214,800 214,000 213,000 212,000 211,600 244,700 243,200
Additional paid-in capital 1,700,400 1,643,100 1,578,700 1,496,800 1,438,100 1,381,600 1,323,900 1,675,900 1,623,300 1,570,400 1,512,300 1,449,400 1,384,400 1,341,200 1,209,500 1,229,100 1,166,900 1,129,500 1,267,000 1,207,600
Retained earnings 6,068,100 5,732,800 5,392,700 4,903,200 4,565,000 4,255,500 3,930,300 4,052,200 3,741,600 3,461,400 3,186,700 2,944,400 2,694,700 2,687,700 2,461,800 2,179,100 1,962,100 1,964,900 4,331,900 4,145,800
Accumulated other comprehensive loss (157,700) (155,400) (159,600) (172,400) (161,100) (157,900) (146,100) (152,000) (156,000) (155,800) (138,200) (141,200) (138,500) (139,000) (150,800) (121,300) (132,700) (142,700) (157,800) (181,500)
Treasury stock, at cost (2,416,900) (2,320,400) (2,318,600) (2,206,700) (1,904,100) (1,903,900) (1,902,500) (1,893,500) (1,278,700) (1,278,700) (1,277,400) (1,021,100) (1,015,400) (743,400) (570,300) (254,200) (252,100) (800) (2,746,200) (2,672,400)
Stockholders’ equity 5,835,900 5,541,300 5,133,300 4,658,400 4,574,300 4,210,300 3,839,100 3,901,100 4,148,300 3,814,800 3,500,300 3,447,500 3,140,400 3,361,300 3,164,200 3,245,700 2,956,200 3,162,500 2,939,600 2,742,700
Total liabilities and stockholders’ equity 8,502,600 8,160,300 7,662,100 7,213,700 7,237,100 6,800,800 6,424,100 6,076,100 6,488,100 5,966,300 5,573,500 5,469,300 5,323,700 5,958,200 5,686,100 5,825,100 5,695,800 5,488,400 5,138,500 4,780,400

Based on: 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Edwards Lifesciences Corp. current liabilities increased from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021.
Long-term liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Edwards Lifesciences Corp. long-term liabilities increased from Q2 2021 to Q3 2021 but then decreased significantly from Q3 2021 to Q4 2021.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Edwards Lifesciences Corp. total liabilities increased from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021.
Stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Edwards Lifesciences Corp. stockholders’ equity increased from Q2 2021 to Q3 2021 and from Q3 2021 to Q4 2021.